5.40

4.05% 0.21

After Hours: 5.37 -0.03 -0.56%

Abeona Therapeutics Inc (ABEO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Abeona Therapeutics Inc stock is traded at $5.40, with a volume of 906.19K. It is up +4.05% in the last 24 hours and up +13.45% over the past month. Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Previous Close:

$5.19

Open:

$5.21

24h Volume:

906.19K

Relative Volume:

0.72

Market Cap:

$308.06M

Revenue:

$5.82M

Net Income/Loss:

$71.18M

P/E Ratio:

5.4152

EPS:

0.9972

Net Cash Flow:

$-84.30M

1W Performance:

+10.88%

1M Performance:

+13.45%

6M Performance:

-2.35%

1Y Performance:

+9.76%

1-Day Range:

$5.145

$5.445

1-Week Range:

$4.81

$5.445

52-Week Range:

$4.00

$7.5401

Abeona Therapeutics Inc Stock (ABEO) Company Profile

Name

Abeona Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

646-813-4701

Address

6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY

Employee

226

Twitter

@abeonabio

Next Earnings Date

2026-03-17

Latest SEC Filings

ABEO's Discussions on Twitter

Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABEO Abeona Therapeutics Inc	5.40	296.08M	5.82M	71.18M	-84.30M	0.9972
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
Mar-05-25	Initiated	Oppenheimer	Outperform
Jul-03-24	Initiated	H.C. Wainwright	Buy
May-30-24	Initiated	Stifel	Buy
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-18-20	Initiated	B. Riley FBR	Buy
Feb-10-20	Initiated	SVB Leerink	Outperform
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-26-19	Downgrade	Mizuho	Buy → Neutral
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy
Jun-05-18	Initiated	Seaport Global Securities	Buy
Nov-08-17	Initiated	SunTrust	Buy
Oct-16-17	Reiterated	H.C. Wainwright	Buy
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight
Oct-10-17	Initiated	Citigroup	Buy
Oct-05-17	Reiterated	Maxim Group	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-18-17	Reiterated	Maxim Group	Buy
Jun-22-17	Resumed	Jefferies	Buy
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy

View All

Abeona Therapeutics Inc Stock (ABEO) Latest News

Apr 15, 2026

JPMorgan Chase & Co. Trims Position in Abeona Therapeutics Inc. $ABEO - MarketBeat

Apr 09, 2026

Aberdeen Group Invests $3.25M in Abeona Therapeutics - National Today

Apr 09, 2026

Aberdeen Group plc Makes New $3.25 Million Investment in Abeona Therapeutics Inc. $ABEO - MarketBeat

Apr 09, 2026

ABEO Should I Buy - Intellectia AI

Apr 09, 2026

Apr 08, 2026

Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair - The Globe and Mail

Apr 08, 2026

Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors - Sahm

Apr 08, 2026

Apr 07, 2026

Abeona Therapeutics names Keith Goldan to board of directors By Investing.com - Investing.com Canada

Apr 07, 2026